A simple smear test for cervical cancer can now pick up ovarian and endometrial cancers before they turn deadly. Ovarian and endometrial cancers are the fifth and sixth leading causes of cancer deaths in women. They are difficult to treat because they often spread to other parts of the body before symptoms arise. A smear test, also known as a Pap test, uses a brush to collect cells from the cervix. To continue reading this premium article, subscribe for unlimited access.
A new project, funded by Ovarian Cancer Action, aims to improve uptake of genetic testing in women with ovarian cancer, especially in Black, Asian and Minority Ethnic groups that currently have the lowest rates of testing. The additional molecular information this testing provides helps doctors and patients choose the best, personalised treatment options. The project team, which includes patients treated at Addenbrooke's and hospitals in Birmingham, will explore why some groups of women decline genetic testing after being diagnosed with ovarian cancer. The team will work with patient groups representing people from ethnic minorities to identify any barriers and misconceptions around genetic testing. One area already highlighted is the lack of informed decision-making resources for women whose first language is not English.
In this Sept. 18, 2017 photo, Teri Giangreco, of Vancouver, who was diagnosed with ovarian cancer in January and is still undergoing treatment stands for a portrait at Salmon Creek Medical Center in Vancouver, Wash. Giangreco didn't know the warning signs of ovarian cancer until after her diagnosis, so she's teamed up with Legacy Salmon Creek Medical Center and the Ovarian Cancer Alliance of Oregon and Southwest Washington to spread the word about signs and symptoms.
A new targeted treatment for ovarian cancer has shown "very promising" results in women in the advanced stages of the disease. It shrunk tumours in around half of women who took part in a small trial. Researchers had only been testing the drug to see if it was safe for humans to take, but found it had an almost instant clinical effect. It is hoped the drug could help women who have stopped responding to all other currently available treatments. So far, it has only been tested in 15 women, and the researchers say it may not be safe to take for more than a few months.